Targeting L1 cell adhesion molecule expression using liposomeencapsulated siRNA suppresses prostate cancer bone metastasis and growth

Shian Ying Sung, I. Hui Wu, Pei Hsin Chuang, John A. Petros, Hsi Chin Wu, Hong Jie Zeng, Wei Chien Huang, Leland W K Chung, Chia Ling Hsieh

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The L1 cell adhesion molecule (L1CAM) has been implicated in tumor progression of many types of cancers, but its role in prostate cancer and its application in targeted gene therapy have not been investigated. Herein, we demonstrated that the L1CAM was expressed in androgen-insensitive and highly metastatic human prostate cancer cell lines. The correlation between L1CAM expression and prostate cancer metastasis was also validated in serum samples of prostate cancer patients. Knockdown of L1CAM expression in prostate cancer cells by RNA interference significantly decreased their aggressive behaviors, including colony formation, migration and invasion in vitro, and tumor formation in a metastatic murine model. These anti-malignant phenotypes of L1CAM-knockdown cancer cells were accompanied by G0/G1 cell cycle arrest and suppression of matrix metalloproteinase (MMP)-2 and MMP-9 expression and nuclear factor NF-κB activation. In vivo targeting of L1CAM expression using liposomeencapsulated L1CAM siRNAs effectively inhibited prostate cancer growth in mouse bone, which was associated with decreased L1CAM expression and cell proliferation by tumor cells. These results provide the first evidence for L1CAM being a major contributor to prostate cancer metastasis and translational application of siRNA-based L1CAM-targeted therapy.

Original languageEnglish
Pages (from-to)9911-9929
Number of pages19
JournalOncotarget
Volume5
Issue number20
Publication statusPublished - 2014

Fingerprint

Neural Cell Adhesion Molecule L1
Bone Neoplasms
Bone Development
Small Interfering RNA
Prostatic Neoplasms
Neoplasm Metastasis
Neoplasms
G1 Phase Cell Cycle Checkpoints
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
RNA Interference
Genetic Therapy
Androgens

Keywords

  • Bone metastasis
  • Gene therapy
  • L1 cell adhesion molecule (L1CAM)
  • Prostate cancer
  • Small interfering RNA (siRNA)

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting L1 cell adhesion molecule expression using liposomeencapsulated siRNA suppresses prostate cancer bone metastasis and growth. / Sung, Shian Ying; Wu, I. Hui; Chuang, Pei Hsin; Petros, John A.; Wu, Hsi Chin; Zeng, Hong Jie; Huang, Wei Chien; Chung, Leland W K; Hsieh, Chia Ling.

In: Oncotarget, Vol. 5, No. 20, 2014, p. 9911-9929.

Research output: Contribution to journalArticle

Sung, SY, Wu, IH, Chuang, PH, Petros, JA, Wu, HC, Zeng, HJ, Huang, WC, Chung, LWK & Hsieh, CL 2014, 'Targeting L1 cell adhesion molecule expression using liposomeencapsulated siRNA suppresses prostate cancer bone metastasis and growth', Oncotarget, vol. 5, no. 20, pp. 9911-9929.
Sung, Shian Ying ; Wu, I. Hui ; Chuang, Pei Hsin ; Petros, John A. ; Wu, Hsi Chin ; Zeng, Hong Jie ; Huang, Wei Chien ; Chung, Leland W K ; Hsieh, Chia Ling. / Targeting L1 cell adhesion molecule expression using liposomeencapsulated siRNA suppresses prostate cancer bone metastasis and growth. In: Oncotarget. 2014 ; Vol. 5, No. 20. pp. 9911-9929.
@article{e6f9548d29b141f884cef38bac82583b,
title = "Targeting L1 cell adhesion molecule expression using liposomeencapsulated siRNA suppresses prostate cancer bone metastasis and growth",
abstract = "The L1 cell adhesion molecule (L1CAM) has been implicated in tumor progression of many types of cancers, but its role in prostate cancer and its application in targeted gene therapy have not been investigated. Herein, we demonstrated that the L1CAM was expressed in androgen-insensitive and highly metastatic human prostate cancer cell lines. The correlation between L1CAM expression and prostate cancer metastasis was also validated in serum samples of prostate cancer patients. Knockdown of L1CAM expression in prostate cancer cells by RNA interference significantly decreased their aggressive behaviors, including colony formation, migration and invasion in vitro, and tumor formation in a metastatic murine model. These anti-malignant phenotypes of L1CAM-knockdown cancer cells were accompanied by G0/G1 cell cycle arrest and suppression of matrix metalloproteinase (MMP)-2 and MMP-9 expression and nuclear factor NF-κB activation. In vivo targeting of L1CAM expression using liposomeencapsulated L1CAM siRNAs effectively inhibited prostate cancer growth in mouse bone, which was associated with decreased L1CAM expression and cell proliferation by tumor cells. These results provide the first evidence for L1CAM being a major contributor to prostate cancer metastasis and translational application of siRNA-based L1CAM-targeted therapy.",
keywords = "Bone metastasis, Gene therapy, L1 cell adhesion molecule (L1CAM), Prostate cancer, Small interfering RNA (siRNA)",
author = "Sung, {Shian Ying} and Wu, {I. Hui} and Chuang, {Pei Hsin} and Petros, {John A.} and Wu, {Hsi Chin} and Zeng, {Hong Jie} and Huang, {Wei Chien} and Chung, {Leland W K} and Hsieh, {Chia Ling}",
year = "2014",
language = "English",
volume = "5",
pages = "9911--9929",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "20",

}

TY - JOUR

T1 - Targeting L1 cell adhesion molecule expression using liposomeencapsulated siRNA suppresses prostate cancer bone metastasis and growth

AU - Sung, Shian Ying

AU - Wu, I. Hui

AU - Chuang, Pei Hsin

AU - Petros, John A.

AU - Wu, Hsi Chin

AU - Zeng, Hong Jie

AU - Huang, Wei Chien

AU - Chung, Leland W K

AU - Hsieh, Chia Ling

PY - 2014

Y1 - 2014

N2 - The L1 cell adhesion molecule (L1CAM) has been implicated in tumor progression of many types of cancers, but its role in prostate cancer and its application in targeted gene therapy have not been investigated. Herein, we demonstrated that the L1CAM was expressed in androgen-insensitive and highly metastatic human prostate cancer cell lines. The correlation between L1CAM expression and prostate cancer metastasis was also validated in serum samples of prostate cancer patients. Knockdown of L1CAM expression in prostate cancer cells by RNA interference significantly decreased their aggressive behaviors, including colony formation, migration and invasion in vitro, and tumor formation in a metastatic murine model. These anti-malignant phenotypes of L1CAM-knockdown cancer cells were accompanied by G0/G1 cell cycle arrest and suppression of matrix metalloproteinase (MMP)-2 and MMP-9 expression and nuclear factor NF-κB activation. In vivo targeting of L1CAM expression using liposomeencapsulated L1CAM siRNAs effectively inhibited prostate cancer growth in mouse bone, which was associated with decreased L1CAM expression and cell proliferation by tumor cells. These results provide the first evidence for L1CAM being a major contributor to prostate cancer metastasis and translational application of siRNA-based L1CAM-targeted therapy.

AB - The L1 cell adhesion molecule (L1CAM) has been implicated in tumor progression of many types of cancers, but its role in prostate cancer and its application in targeted gene therapy have not been investigated. Herein, we demonstrated that the L1CAM was expressed in androgen-insensitive and highly metastatic human prostate cancer cell lines. The correlation between L1CAM expression and prostate cancer metastasis was also validated in serum samples of prostate cancer patients. Knockdown of L1CAM expression in prostate cancer cells by RNA interference significantly decreased their aggressive behaviors, including colony formation, migration and invasion in vitro, and tumor formation in a metastatic murine model. These anti-malignant phenotypes of L1CAM-knockdown cancer cells were accompanied by G0/G1 cell cycle arrest and suppression of matrix metalloproteinase (MMP)-2 and MMP-9 expression and nuclear factor NF-κB activation. In vivo targeting of L1CAM expression using liposomeencapsulated L1CAM siRNAs effectively inhibited prostate cancer growth in mouse bone, which was associated with decreased L1CAM expression and cell proliferation by tumor cells. These results provide the first evidence for L1CAM being a major contributor to prostate cancer metastasis and translational application of siRNA-based L1CAM-targeted therapy.

KW - Bone metastasis

KW - Gene therapy

KW - L1 cell adhesion molecule (L1CAM)

KW - Prostate cancer

KW - Small interfering RNA (siRNA)

UR - http://www.scopus.com/inward/record.url?scp=84930467771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930467771&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 9911

EP - 9929

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 20

ER -